Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Gail L TorkildsenBepotastine Besilate Ophthalmic Solutions Clinical Study Group

Abstract

Bepotastine besilate is a selective histamine1-receptor antagonist and mast cell stabilizer with inhibitory effects on eosinophilic activity. To evaluate the safety and efficacy of 1.5% bepotastine besilate ophthalmic solution in alleviating nonocular symptoms induced by a conjunctival allergen challenge (CAC), a clinical model of allergic conjunctivitis. This was a single-center, double-masked, randomized, placebo-controlled clinical trial performed from March 1 to April 4, 2007. Patients 10 years or older with a history of allergic conjunctivitis and a reproducible, positive, clinical response to a CAC were eligible. Patients received either placebo or 1.5% bepotastine besilate, 1 drop in each eye. After 15 minutes, 8 hours, or 16 hours after dosing, a CAC was performed and patients evaluated nonocular symptoms using standardized grading scales. Seventy-one patients were enrolled in the study, and 66 comprised the per protocol population. A clinically meaningful reduction (> or = 1.0 unit) compared to placebo was achieved for rhinorrhea and nasal congestion at most time points after 1.5% bepotastine besilate instillation at 8 hours before a CAC test. Significant reductions (P < or = .05) in mean values were seen with 1.5% bep...Continue Reading

References

Oct 11, 1990·The New England Journal of Medicine·J BousquetP Godard
Jul 1, 1997·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·N YatoH Narita
Oct 6, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·M B Abelson
Mar 15, 2002·Current Allergy and Asthma Reports·A Keane-Myers
Jun 7, 2003·Current Allergy and Asthma Reports·Mark B Abelson, Oliver Loeffler
May 6, 2004·Current Opinion in Allergy and Clinical Immunology·Inga HansenKarl Hörmann
Nov 13, 2004·The Journal of Allergy and Clinical Immunology·Erwin W Gelfand
Nov 26, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·George W OuslerMark B Abelson
Feb 24, 2006·The American Journal of Medicine·Bruce M Prenner, Eric Schenkel
Oct 4, 2006·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Josefine Gradman, Ole D Wolthers
Oct 18, 2006·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·William BergerEli O Meltzer

❮ Previous
Next ❯

Citations

Jun 9, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jon I WilliamsUNKNOWN Bepotastine Besilate Ophthalmic Solutions Study Group
Nov 7, 2013·Expert Opinion on Pharmacotherapy·Leonard BieloryAndrea McMunn
May 7, 2015·Expert Opinion on Pharmacotherapy·Mark B AbelsonLisa M Smith
Nov 1, 2011·The Journal of Allergy and Clinical Immunology·F Estelle R Simons, Keith J Simons
Feb 27, 2016·International Forum of Allergy & Rhinology·Sule ComertAli Fuat Kalyoncu
Sep 13, 2018·Expert Opinion on Pharmacotherapy·Ismael Carrillo-MartinVes Dimov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.